Prostaglandins

Prostaglandins

 

 

Travoprost,157283-68-6
Travoprost
Travoprost,157283-68-6
CAS
157283-68-6
Molecular Formula
C26H35F3O6 
Molecular Weight
500.551
Systematic Name
5-Heptenoic acid, 7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((1E,3R)-3-hydroxy-4-(3-(trifluoromethyl)phenoxy)-1-
butenyl)cyclopentyl)-, 1-methylethyl ester, (5Z)- 
Assay
98.0%
Certificate of analysis
Travoprost,157283-68-6
View via PDF file
Travoprost,157283-68-6
Specification
Appearance
Colorless or pale yellow oil
Complies
Identification
(1) by HPLC
Complies
(2) by TLC
Complies
Optical rotation
+52.0º to +58.0º
54.7º
Water
Not more than 1.0%
0.79%
Limit of Ethyl acetate
Not more than 0.5%
Not detected
Residual substance
Travoprost acid: N.M.T:0.2%
Not detected
Epoxide derivative: N.M.T:0.4%
Not detected
15-epi diastereomer: N.M.T:0.1%
Not detected
5,6-trans Travoprost: N.M.T:3.5%
Not detected
15-keto derivative: N.M.T:0.3%
Not detected
Any single impurity: N.M.T:0.1%
Not detected
Total impurities: N.M.T:4.0%
Not detected
Residual solvents
Acetonitrile: N.M.T:0.04%
Not detected
Ethanol: N.M.T:0.5%
0.068%
n-Hexane: N.M.T:0.05%
Not detected
IPA: N.M.T:0.5%
0.48%
Dichloromethane: N.M.T:0.06%
Not detected
Assay
96.0% to 102.0%
98.7%
Contact us for more information
Chemical information
Compound Name*
CAS No. "N/A" if the CAS not available*
Quantity*
Contact information
Contact person*
Email Address *
Tel No.*
Company or Organization Name*
Shipping Address*
Country
Remarks

<Privacy policy: the contact information will be only used for this business contact>

Related Prostagandins
Patent Disclaimer
PD1
Products protected by valid patents are not offered for sale in jurisdictions where the sale of such products constitutes a patent infringement. The current list only reflects the products and technologies that are available, under development: note that some products may be developed or produced for internal and experimental uses with no commercal aim.
PD2
Sales of products are limited to those allowed by Chapter VII PLPRC 63, the above includes Research and development quantities.
PD3
the buyer assumes responsibility of all patent considerations in the use of
Lano ’s Pharmaceutical Co.,Ltd product(Travoprost,157283-68-6).
PD4
R&D use in accordance with (1) 35 USC 271(e)+A13(1) in the U.S.; (2) Section 69.1 of Japanese Patent Law in Japan; (3) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (4) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (5) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (6) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (7) such similar laws and rules as may apply in various other countries.